CA3066571A1

CA3066571A1 - Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer

Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer Download PDF

Info

Publication number: CA3066571A1
Authority: CA; Canada
Prior art keywords: siglec; antibody; human; agent; seq
Prior art date: 2017-07-10
Legal status : Pending

Application number

CA3066571A

Other languages

English (en)

French (fr)

Inventor

Stephanie Cornen

Benjamin Rossi

Nicolai Wagtmann

Current Assignee

Innate Pharma SA

Original Assignee

Innate Pharma SA

Priority date

2017-07-10

Filing date

2018-07-09

Publication date

2019-01-17

2018-07-09 Application filed by Innate Pharma SA filed Critical Innate Pharma SA

2019-01-17 Publication of CA3066571A1 publication Critical patent/CA3066571A1/en

Status Pending legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 120
101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 title claims description 384
102000045929 human SIGLEC9 Human genes 0.000 title claims description 85
201000011510 cancer Diseases 0.000 title claims description 68
238000002648 combination therapy Methods 0.000 title 1
108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims abstract description 200
102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims abstract description 199
230000002401 inhibitory effect Effects 0.000 claims abstract description 122
238000011282 treatment Methods 0.000 claims abstract description 53
102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 300
108090000765 processed proteins & peptides Proteins 0.000 claims description 260
230000027455 binding Effects 0.000 claims description 256
229920001184 polypeptide Polymers 0.000 claims description 252
102000004196 processed proteins & peptides Human genes 0.000 claims description 252
210000004027 cell Anatomy 0.000 claims description 231
101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 214
239000003795 chemical substances by application Substances 0.000 claims description 196
210000000822 natural killer cell Anatomy 0.000 claims description 172
102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 171
125000003275 alpha amino acid group Chemical group 0.000 claims description 150
102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 120
101150069255 KLRC1 gene Proteins 0.000 claims description 112
101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 112
238000000034 method Methods 0.000 claims description 93
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 92
239000003446 ligand Substances 0.000 claims description 90
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 89
102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 52
101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 52
210000004698 lymphocyte Anatomy 0.000 claims description 52
230000003013 cytotoxicity Effects 0.000 claims description 48
231100000135 cytotoxicity Toxicity 0.000 claims description 48
230000035772 mutation Effects 0.000 claims description 48
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 45
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 45
102000050701 human SIGLEC7 Human genes 0.000 claims description 43
101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims description 41
125000000539 amino acid group Chemical group 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 39
102000057310 human KLRC1 Human genes 0.000 claims description 33
230000000694 effects Effects 0.000 claims description 30
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 28
238000000684 flow cytometry Methods 0.000 claims description 23
238000002784 cytotoxicity assay Methods 0.000 claims description 20
231100000263 cytotoxicity test Toxicity 0.000 claims description 20
238000009472 formulation Methods 0.000 claims description 20
230000003472 neutralizing effect Effects 0.000 claims description 20
239000008194 pharmaceutical composition Substances 0.000 claims description 17
230000002829 reductive effect Effects 0.000 claims description 15
125000005629 sialic acid group Chemical group 0.000 claims description 13
238000000338 in vitro Methods 0.000 claims description 11
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 9
101710143288 Sialic acid-binding Ig-like lectin 12 Proteins 0.000 claims description 9
102100027093 Sialic acid-binding Ig-like lectin 12 Human genes 0.000 claims description 9
230000003211 malignant effect Effects 0.000 claims description 9
230000000779 depleting effect Effects 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 7
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 7
101000863880 Homo sapiens Sialic acid-binding Ig-like lectin 6 Proteins 0.000 claims description 7
101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims description 6
102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 claims description 6
101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 claims description 6
102100029947 Sialic acid-binding Ig-like lectin 6 Human genes 0.000 claims description 6
102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 claims description 6
206010009944 Colon cancer Diseases 0.000 claims description 5
101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 claims description 5
108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 5
101710143293 Sialic acid-binding Ig-like lectin 10 Proteins 0.000 claims description 5
102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 claims description 5
102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 claims description 5
239000003550 marker Substances 0.000 claims description 5
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
208000014829 head and neck neoplasm Diseases 0.000 claims description 4
210000005260 human cell Anatomy 0.000 claims description 4
201000001441 melanoma Diseases 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
239000004176 azorubin Substances 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
201000010536 head and neck cancer Diseases 0.000 claims description 2
208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
102000056982 human CD33 Human genes 0.000 claims 3
210000002865 immune cell Anatomy 0.000 abstract description 11
235000001014 amino acid Nutrition 0.000 description 216
150000001413 amino acids Chemical class 0.000 description 208
229940024606 amino acid Drugs 0.000 description 207
108010047041 Complementarity Determining Regions Proteins 0.000 description 66
238000006467 substitution reaction Methods 0.000 description 63
239000000427 antigen Substances 0.000 description 62
108091007433 antigens Proteins 0.000 description 61
102000036639 antigens Human genes 0.000 description 61
235000018102 proteins Nutrition 0.000 description 50
102000004169 proteins and genes Human genes 0.000 description 50
108090000623 proteins and genes Proteins 0.000 description 50
241000989747 Maba Species 0.000 description 45
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 43
239000012634 fragment Substances 0.000 description 39
238000012360 testing method Methods 0.000 description 38
230000003993 interaction Effects 0.000 description 34
238000003556 assay Methods 0.000 description 33
210000001744 T-lymphocyte Anatomy 0.000 description 32
102000005962 receptors Human genes 0.000 description 29
108020003175 receptors Proteins 0.000 description 29
230000014509 gene expression Effects 0.000 description 28
210000004881 tumor cell Anatomy 0.000 description 27
230000001404 mediated effect Effects 0.000 description 25
108060003951 Immunoglobulin Proteins 0.000 description 24
102000018358 immunoglobulin Human genes 0.000 description 24
210000000440 neutrophil Anatomy 0.000 description 24
230000000875 corresponding effect Effects 0.000 description 21
210000004443 dendritic cell Anatomy 0.000 description 21
101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 19
230000004913 activation Effects 0.000 description 17
230000000903 blocking effect Effects 0.000 description 17
208000015181 infectious disease Diseases 0.000 description 17
238000004519 manufacturing process Methods 0.000 description 17
101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 description 16
108010087819 Fc receptors Proteins 0.000 description 16
102000009109 Fc receptors Human genes 0.000 description 16
210000001519 tissue Anatomy 0.000 description 16
230000003416 augmentation Effects 0.000 description 15
210000004408 hybridoma Anatomy 0.000 description 15
230000009089 cytolysis Effects 0.000 description 14
-1 e.g. Proteins 0.000 description 14
230000011664 signaling Effects 0.000 description 14
238000010186 staining Methods 0.000 description 14
208000035473 Communicable disease Diseases 0.000 description 13
101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 13
239000000872 buffer Substances 0.000 description 13
230000003053 immunization Effects 0.000 description 13
210000002540 macrophage Anatomy 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
150000007523 nucleic acids Chemical class 0.000 description 13
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 12
239000011230 binding agent Substances 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
238000002649 immunization Methods 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 12
210000001616 monocyte Anatomy 0.000 description 12
108020004707 nucleic acids Proteins 0.000 description 12
102000039446 nucleic acids Human genes 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
230000002147 killing effect Effects 0.000 description 11
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
239000003814 drug Substances 0.000 description 10
239000012636 effector Substances 0.000 description 10
230000004927 fusion Effects 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
238000006386 neutralization reaction Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 9
101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 9
102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 9
238000007792 addition Methods 0.000 description 9
239000002671 adjuvant Substances 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
230000006870 function Effects 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
230000009467 reduction Effects 0.000 description 9
229940124597 therapeutic agent Drugs 0.000 description 9
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 8
108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 8
201000010099 disease Diseases 0.000 description 8
230000002708 enhancing effect Effects 0.000 description 8
235000013922 glutamic acid Nutrition 0.000 description 8
239000004220 glutamic acid Substances 0.000 description 8
230000003389 potentiating effect Effects 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
239000004472 Lysine Substances 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 7
230000003213 activating effect Effects 0.000 description 7
235000004279 alanine Nutrition 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
230000008901 benefit Effects 0.000 description 7
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
229940072221 immunoglobulins Drugs 0.000 description 7
229960003646 lysine Drugs 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000004471 Glycine Substances 0.000 description 6
210000004322 M2 macrophage Anatomy 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
229960002449 glycine Drugs 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
239000013598 vector Substances 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241001529936 Murinae Species 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
239000012472 biological sample Substances 0.000 description 5
210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
230000016396 cytokine production Effects 0.000 description 5
230000029087 digestion Effects 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
108091008042 inhibitory receptors Proteins 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
201000000050 myeloid neoplasm Diseases 0.000 description 5
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
230000004044 response Effects 0.000 description 5
238000009738 saturating Methods 0.000 description 5
210000004988 splenocyte Anatomy 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 description 4
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
241000699802 Cricetulus griseus Species 0.000 description 4
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 4
101100334524 Homo sapiens FCGR3B gene Proteins 0.000 description 4
101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 4
101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 4
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
101150074862 KLRC3 gene Proteins 0.000 description 4
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 4
102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 4
102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 4
102100022701 NKG2-E type II integral membrane protein Human genes 0.000 description 4
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
108091005461 Nucleic proteins Proteins 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000004590 computer program Methods 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
229960002885 histidine Drugs 0.000 description 4
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
238000013507 mapping Methods 0.000 description 4
210000000581 natural killer T-cell Anatomy 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
238000012216 screening Methods 0.000 description 4
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
210000004989 spleen cell Anatomy 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
230000005909 tumor killing Effects 0.000 description 4
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
241000283707 Capra Species 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
101000836875 Homo sapiens Sialic acid-binding Ig-like lectin 12 Proteins 0.000 description 3
101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 3
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
208000008839 Kidney Neoplasms Diseases 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
102000005348 Neuraminidase Human genes 0.000 description 3
108010006232 Neuraminidase Proteins 0.000 description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 3
238000012452 Xenomouse strains Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
229960003121 arginine Drugs 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
150000002270 gangliosides Chemical class 0.000 description 3
230000012010 growth Effects 0.000 description 3
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
102000049342 human SIGLEC12 Human genes 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000002101 lytic effect Effects 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
230000036963 noncompetitive effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
238000007639 printing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
150000004043 trisaccharides Chemical class 0.000 description 3
244000303258 Annona diversifolia Species 0.000 description 2
235000002198 Annona diversifolia Nutrition 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
102100038080 B-cell receptor CD22 Human genes 0.000 description 2
102100027098 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Human genes 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282836 Camelus dromedarius Species 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
206010057248 Cell death Diseases 0.000 description 2
241000606161 Chlamydia Species 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
101000836774 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 description 2
101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 2
101000709473 Homo sapiens Sialic acid-binding Ig-like lectin 14 Proteins 0.000 description 2
101000709472 Homo sapiens Sialic acid-binding Ig-like lectin 15 Proteins 0.000 description 2
101000709471 Homo sapiens Sialic acid-binding Ig-like lectin 16 Proteins 0.000 description 2
241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102000002698 KIR Receptors Human genes 0.000 description 2
108010043610 KIR Receptors Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
108010063954 Mucins Proteins 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
101000836881 Mus musculus Sialic acid-binding Ig-like lectin 12 Proteins 0.000 description 2
241000186364 Mycobacterium intracellulare Species 0.000 description 2
108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
241000187654 Nocardia Species 0.000 description 2
241001631646 Papillomaviridae Species 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
102100029197 SLAM family member 6 Human genes 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 2
108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 2
102100034370 Sialic acid-binding Ig-like lectin 14 Human genes 0.000 description 2
102100034361 Sialic acid-binding Ig-like lectin 15 Human genes 0.000 description 2
102100034375 Sialic acid-binding Ig-like lectin 16 Human genes 0.000 description 2
102100032855 Sialoadhesin Human genes 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000007402 cytotoxic response Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
102000027596 immune receptors Human genes 0.000 description 2
108091008915 immune receptors Proteins 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
230000006525 intracellular process Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229950001907 monalizumab Drugs 0.000 description 2
108010068617 neonatal Fc receptor Proteins 0.000 description 2
210000002741 palatine tonsil Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000008823 permeabilization Effects 0.000 description 2
238000002823 phage display Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
239000004576 sand Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000037432 silent mutation Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003153 stable transfection Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
229960005267 tositumomab Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000012114 Alexa Fluor 647 Substances 0.000 description 1
206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
108010074708 B7-H1 Antigen Proteins 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000588779 Bordetella bronchiseptica Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
241001647378 Chlamydia psittaci Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000186227 Corynebacterium diphtheriae Species 0.000 description 1
241000723655 Cowpea mosaic virus Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
241000607473 Edwardsiella <enterobacteria> Species 0.000 description 1
241000589566 Elizabethkingia meningoseptica Species 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
241000589565 Flavobacterium Species 0.000 description 1
241000587180 Funastrum odoratum Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000207202 Gardnerella Species 0.000 description 1
241000207201 Gardnerella vaginalis Species 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
108010008488 Glycylglycine Proteins 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
101150074628 HLA-E gene Proteins 0.000 description 1
206010066476 Haematological malignancy Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 1
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
101001109470 Homo sapiens NKG2-E type II integral membrane protein Proteins 0.000 description 1
101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
241000186781 Listeria Species 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
102100023123 Mucin-16 Human genes 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241001467553 Mycobacterium africanum Species 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000186366 Mycobacterium bovis Species 0.000 description 1
241000186363 Mycobacterium kansasii Species 0.000 description 1
241000908167 Mycobacterium lepraemurium Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical class OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 1
FDJKUWYYUZCUJX-PGIATKPXSA-N N-glycoloylneuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 1
102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 1
101150110881 NKG2A gene Proteins 0.000 description 1
108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
244000038458 Nepenthes mirabilis Species 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
244000110797 Polygonum persicaria Species 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101100463797 Rattus norvegicus Pgrmc1 gene Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000606683 Rickettsiaceae Species 0.000 description 1
208000006257 Rinderpest Diseases 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
101100042881 Sambucus nigra SNA-I gene Proteins 0.000 description 1
241000607720 Serratia Species 0.000 description 1
241000607717 Serratia liquefaciens Species 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
108010091769 Shiga Toxin 1 Proteins 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
239000004268 Sodium erythorbin Substances 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241001478878 Streptobacillus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
241000203770 Thermoactinomyces vulgaris Species 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
201000003761 Vaginal carcinoma Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
229960000548 alemtuzumab Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
239000007998 bicine buffer Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000009614 chemical analysis method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
210000003690 classically activated macrophage Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000050 cytotoxic potential Toxicity 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
201000007550 esophagus adenocarcinoma Diseases 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000001343 fallopian tube carcinoma Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229940043257 glycylglycine Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
102000057658 human KLRC2 Human genes 0.000 description 1
102000057660 human KLRC3 Human genes 0.000 description 1
102000048968 human SIGLEC6 Human genes 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000008676 import Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
239000002523 lectin Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
238000013178 mathematical model Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229960000470 omalizumab Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000007500 overflow downdraw method Methods 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
244000045947 parasite Species 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
229930192851 perforin Natural products 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
201000006845 reticulosarcoma Diseases 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229940001593 sodium carbonate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
208000017572 squamous cell neoplasm Diseases 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
239000004308 thiabendazole Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000012929 tonicity agent Substances 0.000 description 1
239000008181 tonicity modifier Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
108020005087 unfolded proteins Proteins 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000013013 vulvar carcinoma Diseases 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
229940099073 xolair Drugs 0.000 description 1